Immunic, Inc. (IMUX) announced new Phase 2 CALLIPER trial data for vidofludimus calcium (IMU-838) in progressive multiple sclerosis (PMS) at the 2026 ...
Bullish
Immunic (Nasdaq: IMUX) announced new Phase 2 CALLIPER trial data for vidofludimus calcium in progressive multiple sclerosis, presented at the 2026 CMS...
Bullish
Immunic Inc. (NASDAQ: IMUX) has appointed Erik Lundgren, a former Genentech executive with extensive experience in multiple sclerosis, as its new CEO,...